https://mindmedicinelaw.com/briefing/fda-reorganization-impacts-on-psychedelic-drug-approval-20260729-26961The Psychedelic Journalen2026-07-29T15:05:46.697012+00:00FDA Reorganization: Impacts on Psychedelic Drug ApprovalFDA reorganization, psychedelic drug approval, regulatory efficiency, clinical trials, drug evaluation, market entry, psychedelic research, FDA policy, drug approval timelineshttps://mindmedicinelaw.com/briefing/dea-s-new-data-collection-rule-for-psychedelics-implications-20260729-26960The Psychedelic Journalen2026-07-29T15:05:34.929423+00:00DEA's New Data Collection Rule for Psychedelics: ImplicationsDEA, suspicious orders, controlled substances, psychedelic compounds, regulatory compliance, market dynamics, operational practices, data collection, industry impacthttps://mindmedicinelaw.com/briefing/vet-students-psychedelic-attitudes-impact-therapy-outlook-20260728-27141The Psychedelic Journalen2026-07-29T22:05:52.782672+00:00Vet Students' Psychedelic Attitudes Impact Therapy Outlookveterinary medicine, psychedelic therapies, student attitudes, treatment expectations, educational impact, cognitive frameworkshttps://mindmedicinelaw.com/briefing/hepatic-safety-of-ketamine-and-esketamine-for-trd-patients-20260728-27190The Psychedelic Journalen2026-07-29T22:05:37.332493+00:00Hepatic Safety of Ketamine and Esketamine for TRD Patientsketamine, esketamine, treatment-resistant depression, hepatic safety, liver monitoring, clinical trials, mental health treatment, Mayo Clinic, subanesthetic doseshttps://mindmedicinelaw.com/briefing/neuroimmune-signaling-in-ketamine-and-psychedelic-antidepressant-response-20260728-27189The Psychedelic Journalen2026-07-29T22:05:28.268957+00:00Neuroimmune Signaling in Ketamine and Psychedelic Antidepressant Responseneuroimmune signaling, ketamine, psychedelics, antidepressant response, IL-15, MCP-1, cytokine ratios, treatment-resistant depression, biomarkers, clinical trialshttps://mindmedicinelaw.com/briefing/biomarkers-in-bipolar-disorder-ketamine-psychedelics-20260728-26887The Psychedelic Journalen2026-07-28T22:06:02.896903+00:00Biomarkers in Bipolar Disorder: Ketamine & Psychedelicsbipolar disorder, biomarkers, ketamine, psychedelic interventions, clinical trials, precision medicine, patient outcomes, psychiatric treatment, neuroscience, public healthhttps://mindmedicinelaw.com/briefing/hepatic-safety-of-ketamine-in-depression-treatment-new-insights-20260728-26920The Psychedelic Journalen2026-07-28T22:05:54.773163+00:00Hepatic Safety of Ketamine in Depression Treatment: New Insightsketamine, esketamine, hepatic safety, treatment-resistant depression, clinical guidelines, liver function, psychiatric treatmenthttps://mindmedicinelaw.com/briefing/fda-pediatric-advisory-committee-meeting-implications-for-psychedelic-research-20260728-26614The Psychedelic Journalen2026-07-28T15:06:11.997235+00:00FDA Pediatric Advisory Committee Meeting: Implications for Psychedelic ResearchFDA Pediatric Advisory Committee, psychedelic research minors, pediatric psychedelic therapies, FDA public meeting, psychedelic regulatory issues, pediatric clinical trials, psychedelic safety children, public health policy psychedelicshttps://mindmedicinelaw.com/briefing/cardiovascular-risks-of-sympathomimetic-drugs-implications-20260727-27161The Psychedelic Journalen2026-07-29T22:06:12.472828+00:00Cardiovascular Risks of Sympathomimetic Drugs: Implicationssympathomimetic drugs, cardiovascular risks, cocaine, amphetamines, clinical guidelines, toxicological testing, emergency department, catecholamine excess, myocardial toxicity, individualized treatmenthttps://mindmedicinelaw.com/briefing/ketamine-assisted-psychotherapy-for-depression-current-research-20260727-27142The Psychedelic Journalen2026-07-29T22:06:04.255782+00:00Ketamine-Assisted Psychotherapy for Depression: Current Researchketamine-assisted psychotherapy, depression treatment, randomized controlled trials, psychotherapy models, mental health research, cognitive behavioral therapy, treatment-resistant depression, clinical guidelines, psychotherapy integration, ketamine riskshttps://mindmedicinelaw.com/briefing/psychedelics-and-chronic-pain-mechanisms-and-barriers-20260727-27143The Psychedelic Journalen2026-07-29T22:05:43.544928+00:00Psychedelics and Chronic Pain: Mechanisms and Barrierspsychedelics, chronic pain, central nervous system, neuroplasticity, clinical trials, expectancy bias, analgesics, neuroscience, pain management, translational barriershttps://mindmedicinelaw.com/briefing/medicine-4-0-revolutionizing-access-in-psychedelics-20260727-26825The Psychedelic Journalen2026-07-29T15:05:55.370265+00:00Medicine 4.0: Revolutionizing Access in Psychedelicsmedicine 4.0, psychedelic research, equitable access, healthcare policy, regulatory frameworks, scientific knowledge, digital health technologies, public health inequalities, commercial incentives, structural obstructionshttps://mindmedicinelaw.com/briefing/psilocybin-microdosing-for-depression-current-evidence-review-20260727-26805The Psychedelic Journalen2026-07-28T22:06:39.550625+00:00Psilocybin Microdosing for Depression: Current Evidence Reviewpsilocybin microdosing, depression treatment, psychedelic research, clinical trials, mental health, methodological limitations, serotonin receptors, placebo effects, ethical considerations, psychedelic therapieshttps://mindmedicinelaw.com/briefing/eeg-spectral-power-decodes-ketamine-state-implications-for-research-20260726-26843The Psychedelic Journalen2026-07-28T22:06:22.147233+00:00EEG Spectral Power Decodes Ketamine State: Implications for ResearchEEG spectral power, ketamine state decoding, phase connectivity, psychedelic research, neural correlates, EEG-based diagnostics, subanaesthetic ketamine, consciousness, cross-subject transferability, psychedelic stateshttps://mindmedicinelaw.com/briefing/ketamine-s-role-in-treating-depression-in-bpd-a-review-20260726-26857The Psychedelic Journalen2026-07-28T22:06:11.575742+00:00Ketamine's Role in Treating Depression in BPD: A Reviewketamine, borderline personality disorder, depression, suicidality, clinical trials, psychedelic research, mental health, pharmacology, NMDA receptor, treatment-resistant depressionhttps://mindmedicinelaw.com/briefing/elunetirom-s-role-in-enhancing-neuroplasticity-explored-20260725-26859The Psychedelic Journalen2026-07-28T22:06:30.618306+00:00Elunetirom's Role in Enhancing Neuroplasticity Exploredelunetirom, neuroplasticity, thyroid hormone receptor, major depressive disorder, bipolar depression, mitochondrial biogenesis, psychiatric disorders, clinical trials, brain-targeted therapy, thyromimetic signaling